Adaptimmune Therapeutics Stock News

Los Angeles, USA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Advanced Hepatocellular Carcinoma Enters Clinical Trials | DelveInsight There are a plethora of companies developing therapies to treat Advanced Hepatocellular Carcinoma. CStone Pharmaceuticals has its drug candidate in the most advanced stage (Phase III). DelveInsight''s " Advanced Hepatocellular Carcinoma Pipeline Insight " report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscapes. It comprises Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Advanced Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Advanced Hepatocellular Carcinoma pipeline products. Some of the key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report Major companies such as CStone Pharmaceuticals, Akesobio, Chia Tai Tianqing Pharmaceutical Group, Yiviva Inc., BeiGene, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Carsgen Therapeutics, Ltd., Jiangsu Alphamab Biopharmaceuticals, Sunshine Lake Pharma Co., Ltd., AVEO Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Sinocelltech Ltd., LTD, Eureka Therapeutics Inc., Taizhou Hanzhong biomedical co.

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript

These two small-cap cancer companies would be a perfect fit for Pfizer.

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and

These two novel-drug makers could be top takeover targets next year.

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -

Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.

Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therap

The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased by over 10% pre-market today. This is why it happened.

- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased 28.95% today. This is why it happened.